PMID- 20885384
OWN - NLM
STAT- MEDLINE
DCOM- 20111004
LR  - 20211020
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Print)
IS  - 1930-7381 (Linking)
VI  - 19
IP  - 3
DP  - 2011 Mar
TI  - Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in 
      mice with diet-induced obesity.
PG  - 505-13
LID - 10.1038/oby.2010.213 [doi]
AB  - We studied whether cannabinoid receptor (CB1) blockade with rimonabant has an 
      anti-inflammatory effect in obese mice, and whether this effect depends on weight 
      loss and/or diet consumption. High-fat diet (HFD)-induced obese mice were treated 
      orally with rimonabant (HFD-R) or vehicle (HFD-V) for 4 weeks. Paired-feeding was 
      conducted in two additional groups of obese mice to achieve either the same body 
      weight (HFD-BW) or the same HFD intake (HFD DI) as HFD-R. All these groups of 
      mice were maintained on HFD throughout, with mice on normal diet (ND) throughout 
      as lean controls. Rimonabant treatment of obese mice induced marked diet-intake 
      reduction and weight loss during the first week, which was followed by 
      maintenance of low body weight but not diet-intake reduction. Lower HFD intake 
      was required to reach the same degree of weight loss in HFD-BW. HFD-DI had 
      similar weight loss initially, but then started to gain weight, reaching a higher 
      body weight than HFD-R. Despite the same degree of weight loss, HFD-R had less 
      fat mass and lower adipogenic gene expression than HFD-BW. Compared to HFD-V or 
      HFD-DI, HFD-R had reduced inflammation in adipose tissue (AT) and/or liver 
      indicated primarily by lower monocyte chemoattractant protein-1 (MCP-1) levels. 
      However, MCP-1 levels were not significantly different between HFD-R and HFD-BW. 
      In vitro incubation of rimonabant with AT explants did not change MCP-1 levels. 
      Thus, rimonabant induced weight loss in obese mice by diet-intake-dependent and 
      -independent fashions. Rimonabant decreased inflammation in obese mice, possibly 
      through a primary effect on weight reduction.
FAU - Wang, Qun
AU  - Wang Q
AD  - Department of Medicine, Section of Cardiovascular Research, Baylor College of 
      Medicine, Houston, Texas, USA.
FAU - Perrard, Xiaoyuan D
AU  - Perrard XD
FAU - Perrard, Jerry L
AU  - Perrard JL
FAU - Mansoori, Amir
AU  - Mansoori A
FAU - Smith, C Wayne
AU  - Smith CW
FAU - Ballantyne, Christie M
AU  - Ballantyne CM
FAU - Wu, Huaizhu
AU  - Wu H
LA  - eng
GR  - R01 HL098839/HL/NHLBI NIH HHS/United States
GR  - R01 DK078847-03/DK/NIDDK NIH HHS/United States
GR  - R01 DK078847/DK/NIDDK NIH HHS/United States
GR  - R01HL098839/HL/NHLBI NIH HHS/United States
GR  - R01DK078847/DK/NIDDK NIH HHS/United States
GR  - R01 HL098839-02/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100930
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Dietary Fats)
RN  - 0 (Piperidines)
RN  - 0 (Pyrazoles)
RN  - 0 (Receptor, Cannabinoid, CB1)
RN  - RML78EN3XE (Rimonabant)
SB  - IM
MH  - Adipose Tissue/drug effects/pathology
MH  - Animals
MH  - Anti-Obesity Agents/pharmacology/*therapeutic use
MH  - Chemokine CCL2/blood
MH  - Diet/adverse effects
MH  - Dietary Fats/*adverse effects
MH  - Disease Models, Animal
MH  - Energy Intake/drug effects
MH  - Inflammation/blood/*drug therapy/etiology
MH  - Liver/pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Obesity/blood/*drug therapy/etiology
MH  - Piperidines/pharmacology/*therapeutic use
MH  - Pyrazoles/pharmacology/*therapeutic use
MH  - Receptor, Cannabinoid, CB1/*antagonists & inhibitors
MH  - Rimonabant
MH  - Weight Gain/physiology
MH  - Weight Loss/*drug effects/physiology
PMC - PMC3272877
MID - NIHMS352512
EDAT- 2010/10/05 06:00
MHDA- 2011/10/05 06:00
PMCR- 2012/02/06
CRDT- 2010/10/02 06:00
PHST- 2010/10/02 06:00 [entrez]
PHST- 2010/10/05 06:00 [pubmed]
PHST- 2011/10/05 06:00 [medline]
PHST- 2012/02/06 00:00 [pmc-release]
AID - oby2010213 [pii]
AID - 10.1038/oby.2010.213 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2011 Mar;19(3):505-13. doi: 10.1038/oby.2010.213. Epub 
      2010 Sep 30.